BMS To Pay Up To $1.25B For Cancer Drugmaker Flexus
Bristol-Myers Squibb Co. agreed on Monday to buy venture capital-backed startup Flexus Biosciences Inc., a privately held biotech firm developing cancer-fighting therapies, for up to $1.25 billion, upgrading its assets in...To view the full article, register now.
Already a subscriber? Click here to view full article